← Back to Screener
Connect Biopharma Holdings Limited Ordinary Shares (CNTB)
Price$2.34
Value ScoreF
Growth ScoreF
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-36.88%
Price vs S&P 500 (4W)-4.16%
VGM Score28.29
Market Capitalization$156.78M
All Metrics
Book Value / Share (Quarterly)$0.68
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.92
Price vs S&P 500 (YTD)-22.64%
Net Profit Margin (TTM)-21243.35%
EPS (TTM)$-1.15
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-1.15
EPS (Annual)$-1.00
ROI (Annual)-16.96%
Cash / Share (Quarterly)$0.73
Revenue Growth QoQ (YoY)-99.80%
ROA (Last FY)-15.43%
EBITD / Share (TTM)$-1.17
Operating Margin (TTM)-21763.09%
Cash Flow / Share (Annual)$-0.44
P/B Ratio3.68x
P/B Ratio (Quarterly)3.47x
Net Income / Employee (Annual)$-866,900
EV / Revenue (TTM)475.30x
Net Interest Coverage (TTM)-86.06x
ROA (TTM)-97.07%
EPS Incl Extra (Annual)$-1.00
Current Ratio (Annual)11.46x
Quick Ratio (Quarterly)2.86x
3-Month Avg Trading Volume0.22M
52-Week Price Return219.23%
Revenue / Employee (TTM)$3,600
Tangible BV / Share (Quarterly)$0.68
P/S Ratio (Annual)2449.69x
Asset Turnover (Annual)0.26x
52-Week High$3.82
EPS Excl Extra (Annual)$-1.00
CapEx CAGR (5Y)-50.96%
26-Week Price Return-20.95%
Quick Ratio (Annual)11.20x
13-Week Price Return-1.19%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.23x
Enterprise Value$110.75M
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$1,000
Pretax Margin (Annual)-86379.69%
Cash / Share (Annual)$1.69
3-Month Return Std Dev84.88%
Net Income / Employee (TTM)$-1,009,500
ROE (Last FY)-16.96%
EPS Basic Excl Extra (Annual)$-1.00
Receivables Turnover (TTM)58.25x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.15
ROI (TTM)-122.29%
P/S Ratio (TTM)672.88x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.66
Price vs S&P 500 (52W)191.02%
Year-to-Date Return-11.70%
5-Day Price Return5.96%
EPS Normalized (Annual)$-1.00
ROA (5Y Avg)-54.44%
Net Profit Margin (Annual)-86687.50%
Month-to-Date Return0.81%
EBITD / Share (Annual)$-1.03
Operating Margin (Annual)-90740.62%
LT Debt / Equity (Annual)0.00x
EPS Basic Excl Extra (TTM)$-1.15
P/TBV (Quarterly)3.48x
P/B Ratio (Annual)0.83x
Pretax Margin (TTM)-21172.96%
Book Value / Share (Annual)$1.67
Price vs S&P 500 (13W)-10.94%
Beta-0.22x
Revenue / Share (TTM)$0.00
ROE (TTM)-122.29%
52-Week Low$0.73
vGradeF
gGradeF
mGradeB
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-2.35est. -1.54
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.27
4.27
4.27
4.27
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CNTBConnect Biopharma Holdings Limited Ordinary Shares | F | F | B | $2.34 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Connect Biopharma is a clinical-stage biopharmaceutical company developing next-generation immune modulators to treat autoimmune diseases and inflammatory conditions. The company leverages expertise in T cell modulation to build a pipeline of small molecule and antibody candidates targeting key inflammation pathways. Its lead programs include CBP-201, CBP-307, and CBP-174.